Abstract
Based on the approvals of crizotinib and entrectinib by the Food and Drug Administration for the treatment of ROS1-positive non-small lung cancer, we sought to analysis of ROS1 fusions characteristics in Chinese solid tumor patients to explore the possibility of therapeutic intervention in solid tumors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
